Navigation Links
Three Organizations Receive CEO Cancer Gold Standard(TM) Accreditation

Duke Medicine, University of North Dakota and Valeant Pharmaceuticals join

workplace wellness leadership effort

CARY, N.C., Oct. 11 /PRNewswire-USNewswire/ -- Today, three organizations, Duke Medicine, The University of North Dakota and Valeant Pharmaceuticals, were accredited with the CEO Cancer Gold Standard(TM), certifying their commitment to the health of their employees and their families by agreeing to meet an exceptionally high standard of cancer prevention, screening and care guidelines. In doing so, they join with thirteen other organizations that have answered former President George H.W. Bush's call for business leaders to be "bold and venturesome" in their efforts in preventing cancer in the workplace and in their leadership in the overall fight against cancer.

William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs that created the CEO Cancer Gold Standard(TM), in collaboration with leading health professionals. "Adopting the Gold Standard is a tribute to the value these CEOs place on their employees and to the extraordinary leadership they provide their organizations and to all of those committed to winning the battle against cancer."

The CEO Cancer Gold Standard(TM), calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.

Earlier this year, the President's Cancer Panel report, "Promoting Healthy Lifestyles: Policy, Program, and Personal Recommendations for Reducing Cancer Risk," identified the CEO Cancer Gold Standard(TM) as an initiative that is helping reverse negative, unhealthy lifestyle trends and creating hope in the fight against cancer for America's workers and their families.

In addition to Duke Medicine, The University of North Dakota and Valeant Pharmaceuticals, thirteen other companies have received the CEO Cancer Gold Standard(TM) accreditation from the CEO Roundtable on Cancer. They are: American Cancer Society (national headquarters), American Legacy Foundation, AstraZeneca, Edelman, Enzon Pharmaceuticals, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, MD Anderson Cancer Center, Novartis, OSI Pharmaceuticals, Quintiles Transnational and SAS Institute.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives, led by Robert A. Ingram, then the CEO of Glaxo Wellcome, now GlaxoSmithKline, to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard, and have since collaborated with the American Cancer Society to encourage its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please call 866-526-7830 or visit

For more information:

CEO Roundtable on Cancer

John Dornan, Executive Director

P: 919-531-0966


To read the President's Cancer Panel report, please go to:

This release was issued through eReleases(TM). For more information, visit

SOURCE CEO Roundtable on Cancer
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Nobel Prize for Medicine shared by Three scientists
3. Biotechnology industry expected to grow into a three billion dollar industry by 2002
4. Baltimore doctors perform three simultaneous kidney transplants
5. FDA gives “black box warning” against three asthma drus
6. Three Tropical Parasites Genetic Code Unravelled
7. The Future Pattern Of Weight Gain Is Laid As Early As Three Years Of Age
8. Smoking Increases The Risk Of Heart Disease By Three Times
9. Three Sisters Have One Baby and Make History
10. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
11. Three More Bird Flu Cases Reported By China
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: